Introduction: Although studies have suggested that metabolic risk profiles are prognostic factors in kidney transplantation recipients (KTRs), the prognostic value of fatty liver, a known surrogate of metabolic risk, in KTRs remains to be elucidated. The objective of this study was to investigate the association between noninvasive liver biomarkers used to assess hepatic steatotic and fibrotic burdens and graft outcomes in KTRs. Methods: A total of 3,092 patients who underwent deceased or living donor kidney transplantation (KT) between January 2000 and December 2022 were enrolled. Postoperative hepatic fibrotic burdens of KTRs were assessed using the fibrosis-4 (FIB-4) score and the non-alcoholic fatty liver disease fibrosis score (NFS). The primary outcome was a composite of 50% estimated glomerular filtration rate (eGFR) decline and graft failure. Secondary outcomes included individual outcomes of 50% eGFR decline, graft failure, and acute rejection. Results: For the primary outcome, during a mean follow-up of 6.0 years, the composite outcome occurred in 519 (16.8%) participants. When stratified into three groups according to FIB-4 score categories, the highest score group (FIB-4 ≥2.67) had a 2.05-fold (95% confidence interval [CI], 1.44–2.91; p < 0.001) higher risk of the composite outcome compared to the lowest score group (FIB-4 <1.30). Furthermore, the highest score group showed higher risk of the secondary outcomes, with hazard ratios (95% CI) of 1.75 (1.16–2.66), 1.62 (1.06–2.46), and 2.23 (1.43–3.46) for 50% eGFR decline, acute rejection, and graft failure, respectively. Similar findings were observed for NFS. Conclusions: Higher hepatic fibrotic burdens were associated with unfavorable graft outcomes in KTRs.

1.
Eslam
M
,
Newsome
PN
,
Sarin
SK
,
Anstee
QM
,
Targher
G
,
Romero-Gomez
M
, et al
.
A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement
.
J Hepatol
.
2020
;
73
(
1
):
202
9
.
2.
Lonardo
A
,
Nascimbeni
F
,
Mantovani
A
,
Targher
G
.
Hypertension, diabetes, atherosclerosis and NASH: cause or consequence
.
J Hepatol
.
2018
;
68
(
2
):
335
52
.
3.
Li
AA
,
Ahmed
A
,
Kim
D
.
Extrahepatic manifestations of nonalcoholic fatty liver disease
.
Gut Liver
.
2020
;
14
(
2
):
168
78
.
4.
Ballestri
S
,
Zona
S
,
Targher
G
,
Romagnoli
D
,
Baldelli
E
,
Nascimbeni
F
, et al
.
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
.
J Gastroenterol Hepatol
.
2016
;
31
(
5
):
936
44
.
5.
Younossi
ZM
,
Golabi
P
,
Paik
JM
,
Henry
A
,
Van Dongen
C
,
Henry
L
.
The global epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): a systematic review
.
Hepatology
.
2023
;
77
(
4
):
1335
47
.
6.
Hill
NR
,
Fatoba
ST
,
Oke
JL
,
Hirst
JA
,
O'Callaghan
CA
,
Lasserson
DS
, et al
.
Global prevalence of chronic kidney disease - a systematic review and meta-analysis
.
PLoS One
.
2016
;
11
(
7
):
e0158765
.
7.
Jha
V
,
Garcia-Garcia
G
,
Iseki
K
,
Li
Z
,
Naicker
S
,
Plattner
B
, et al
.
Chronic kidney disease: global dimension and perspectives
.
Lancet
.
2013
;
382
(
9888
):
260
72
.
8.
Go
AS
,
Chertow
GM
,
Fan
D
,
McCulloch
CE
,
Hsu
CY
.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
.
N Engl J Med
.
2004
;
351
(
13
):
1296
305
.
9.
Thomas
R
,
Kanso
A
,
Sedor
JR
.
Chronic kidney disease and its complications
.
Prim Care
.
2008
;
35
(
2
):
329
44
, vii.
10.
Byrne
CD
,
Targher
G
.
NAFLD as a driver of chronic kidney disease
.
J Hepatol
.
2020
;
72
(
4
):
785
801
.
11.
Mantovani
A
,
Petracca
G
,
Beatrice
G
,
Csermely
A
,
Lonardo
A
,
Schattenberg
JM
, et al
.
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
.
Gut
.
2022
;
71
(
1
):
156
62
.
12.
Musso
G
,
Cassader
M
,
Cohney
S
,
De Michieli
F
,
Pinach
S
,
Saba
F
, et al
.
Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities
.
Diabetes Care
.
2016
;
39
(
10
):
1830
45
.
13.
Chung
BH
,
Lee
JY
,
Kang
SH
,
Sun
IO
,
Choi
SR
,
Park
HS
, et al
.
Comparison of patient outcome according to renal replacement modality after renal allograft failure
.
Ren Fail
.
2011
;
33
(
3
):
261
8
.
14.
Cohen
E
,
Korah
M
,
Callender
G
,
Belfort de Aguiar
R
,
Haakinson
D
.
Metabolic disorders with kidney transplant
.
Clin J Am Soc Nephrol
.
2020
;
15
(
5
):
732
42
.
15.
Shapiro
R
,
Jordan
M
,
Scantlebury
V
,
Fung
J
,
Jensen
C
,
Tzakis
A
, et al
.
FK 506 in clinical kidney transplantation
.
Transplant Proc
.
1991
;
23
(
6
):
3065
7
.
16.
Haddad
EM
,
McAlister
VC
,
Renouf
E
,
Malthaner
R
,
Kjaer
MS
,
Gluud
LL
.
Cyclosporin versus tacrolimus for liver transplanted patients
.
Cochrane Database Syst Rev
.
2006
;
2006
(
4
):
Cd005161
.
17.
Zelle
DM
,
Corpeleijn
E
,
van Ree
RM
,
Stolk
RP
,
van der Veer
E
,
Gans
RO
, et al
.
Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients
.
Am J Transplant
.
2010
;
10
(
1
):
106
14
.
18.
Yan
J
,
Yang
X
,
Wang
J
,
Cai
H
,
Che
X
,
Ying
L
, et al
.
Metabolic risk profile and graft function deterioration 2 Years after kidney transplant
.
JAMA Netw Open
.
2023
;
6
(
12
):
e2349538
.
19.
Moon
JH
,
Kim
W
,
Koo
BK
,
Cho
NH
;
Innovative Target Exploration of NAFLD ITEN consortium
.
Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease
.
Gut Liver
.
2022
;
16
(
3
):
433
42
.
20.
Cuschieri
S
.
The STROBE guidelines
.
Saudi J Anaesth
.
2019
;
13
(
Suppl 1
):
S31
4
.
21.
European Association for the Study of the Liver
;
Clinical Practice Guideline Panel
;
Chair:
;
EASL Governing Board representative:Panel members
.
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update
.
J Hepatol
.
2021
;
75
(
3
):
659
89
.
22.
Jun
DW
,
Kim
SG
,
Park
SH
,
Jin
SY
,
Lee
JS
,
Lee
JW
, et al
.
External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients
.
J Gastroenterol Hepatol
.
2017
;
32
(
5
):
1094
9
.
23.
Joo
SK
,
Kim
W
,
Kim
D
,
Kim
JH
,
Oh
S
,
Lee
KL
, et al
.
Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease
.
Liver Int
.
2018
;
38
(
2
):
331
41
.
24.
Imajo
K
,
Kessoku
T
,
Honda
Y
,
Tomeno
W
,
Ogawa
Y
,
Mawatari
H
, et al
.
Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography
.
Gastroenterology
.
2016
;
150
(
3
):
626
37.e7
.
25.
Lee
JH
,
Kim
D
,
Kim
HJ
,
Lee
CH
,
Yang
JI
,
Kim
W
, et al
.
Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease
.
Dig Liver Dis
.
2010
;
42
(
7
):
503
8
.
26.
Lameire
NH
,
Levin
A
,
Kellum
JA
,
Cheung
M
,
Jadoul
M
,
Winkelmayer
WC
, et al
.
Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference
.
Kidney Int
.
2021
;
100
(
3
):
516
26
.
27.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
.
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
.
Kidney Int
.
2013
;
3
(
1
):
31
.
28.
Anstee
QM
,
Targher
G
,
Day
CP
.
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
.
Nat Rev Gastroenterol Hepatol
.
2013
;
10
(
6
):
330
44
.
29.
Targher
G
,
Day
CP
,
Bonora
E
.
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
.
N Engl J Med
.
2010
;
363
(
14
):
1341
50
.
30.
Targher
G
,
Chonchol
M
,
Zoppini
G
,
Abaterusso
C
,
Bonora
E
.
Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link
.
J Hepatol
.
2011
;
54
(
5
):
1020
9
.
31.
Mikolasevic
I
,
Racki
S
,
Zaputovic
L
,
Lukenda
V
,
Sladoje-Martinovic
B
,
Orlic
L
.
Nonalcoholic Fatty Liver Disease (NAFLD) and cardiovascular risk in renal transplant recipients
.
Kidney Blood Press Res
.
2014
;
39
(
4
):
308
14
.
32.
Grupper
A
,
Rabinowich
A
,
Ben Shabat
I
,
Tzadok
R
,
Schwartz
D
,
Schwartz
IF
, et al
.
Nonalcoholic fatty liver disease before kidney transplantation correlates with new onset diabetes and poor metabolic outcomes
.
Am J Nephrol
.
2022
;
53
(
8–9
):
636
45
.
33.
Yaseen
RT
,
Laeeq
SM
,
Ismail
H
,
Hanif
FM
,
Tasneem
AA
,
Majid
Z
, et al
.
Etiologies associated with elevated liver enzymes after renal transplant
.
Exp Clin Transplant
.
2024
;
22
(
Suppl 1
):
167
72
.
34.
Bilson
J
,
Mantovani
A
,
Byrne
CD
,
Targher
G
.
Steatotic liver disease, MASLD and risk of chronic kidney disease
.
Diabetes Metab
.
2024
;
50
(
1
):
101506
.
35.
Petta
S
,
Muratore
C
,
Craxì
A
.
Non-alcoholic fatty liver disease pathogenesis: the present and the future
.
Dig Liver Dis
.
2009
;
41
(
9
):
615
25
.
36.
Rau
M
,
Schilling
AK
,
Meertens
J
,
Hering
I
,
Weiss
J
,
Jurowich
C
, et al
.
Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver
.
J Immunol
.
2016
;
196
(
1
):
97
105
.
37.
Afzali
B
,
Lombardi
G
,
Lechler
RI
,
Lord
GM
.
The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease
.
Clin Exp Immunol
.
2007
;
148
(
1
):
32
46
.
38.
Chung
BH
,
Oh
HJ
,
Piao
SG
,
Hwang
HS
,
Sun
IO
,
Choi
SR
, et al
.
Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection
.
Immunology
.
2012
;
136
(
3
):
344
51
.
You do not currently have access to this content.